Biogen Inc.
Revenue Breakdown
| Fiscal Year | TECFIDERA | Interferon (AVONEX+PLEGRIDY combined) | AVONEX | PLEGRIDY | TYSABRI | FAMPYRA | ZINBRYTA | VUMERITY | ELOCTATE | ALPROLIX | FUMADERM | SPINRAZA | ADUHELM | BENEPALI | IMRALDI | FLIXABI | BYOOVIZ | TOFIDENCE | QALSODY | SKYCLARYS | ZURZUVAE | FUMADERM and ADUHELM (combined) | Other Product Revenue | Revenue from anti-CD20 therapeutic programs | Alzheimer's collaboration revenue | Contract manufacturing, royalty and other revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2021 | $1.95B | — | $1.21B | $357.4M | $2.06B | $105.2M | — | $410.4M | — | — | $11.0M | $1.91B | $3.0M | $498.3M | $233.4M | $99.4M | — | — | — | — | — | — | — | $1.66B | — | $476.3M |
| FY2022 | $1.44B | — | $973.5M | $331.9M | $2.03B | $96.6M | — | $553.4M | — | — | $8.2M | $1.79B | $4.8M | $441.0M | $224.5M | $81.3M | $4.3M | — | — | — | — | — | — | $1.70B | — | $485.1M |
| FY2023 | $1.01B | — | $811.0M | $294.7M | $1.88B | $90.5M | — | $576.3M | — | — | — | $1.74B | — | $438.8M | $222.1M | $77.4M | $31.7M | — | $5.9M | $55.9M | — | — | $11.8M | $1.69B | — | $899.3M |
| FY2024 | $967.1M | — | $707.5M | $260.5M | $1.72B | $71.7M | — | $628.0M | — | — | — | $1.57B | — | $479.1M | $213.1M | $63.2M | $36.6M | $1.1M | $32.4M | $382.5M | $72.2M | $10.3M | — | $1.75B | $59.9M | $652.6M |
| FY2025 | $679.7M | — | $695.5M | $250.1M | $1.67B | $1.4M | — | $746.8M | — | — | — | $1.55B | — | $453.2M | $190.2M | $52.6M | $32.4M | $700.0K | $86.9M | $520.5M | $195.1M | $2.1M | — | $1.86B | $177.7M | $732.9M |